IBS :: Effects of Linaclotide Acetate in Patients with IBS
Researchers are continually looking for unique pathways to treat digestive diseases, such as constipation and irritable bowel syndrome.
Placebo
Ulcerative Colitis :: Ligand rosiglitazone for active ulcerative colitis
Currently, 5-aminosalicylic acid (5-ASA) is the most common treatment for ulcerative colitis (UC), a form of inflammatory bowel disease (IBD).
Erectile Dysfunction :: Daily dosing of sildenafil in type 2 diabetic men with erectile dysfunction
It is known that erectile dysfunction (ED), particularly in diabetic men, is often characterized by increased oxidative stress and decreased endothelial function.
BMI :: Body mass index affects the response to sildenafil in men with urinary tract symptoms
A known link has been established between erectile dysfunction (ED) and cardiovascular risk factors such as obesity.
Diabetes :: FDA Issues Safety Alert on GSK’s Avandia to treat type 2 diabetes
The U.S. Food and Drug Administration (FDA) is aware of a potential safety issue related to Avandia (rosiglitazone), a drug approved to treat type 2 diabetes.
COPD :: Drug treatment slows decline in lung function in COPD patients, TORCH study finds
Treatment with a commonly used drug slows the decline in lung function in patients with chronic obstructive pulmonary disease (COPD), according to results from the TORCH (TOwards a Revolution in COPD Health) study presented at the American Thoracic Society 2007 International Conference, on Tuesday, May 22.
Hepatitis C :: Celgosivir with Peginterferon and Ribavirin in Chronic Hepatitis C
Celgosivir is a new class of antiviral medicine in clinical development for the treatment of chronic hepatitis C virus (HCV) infection. Researchers tested this new antiviral medicine and measured its potential to offer improved treatment outcomes when combined with other anti-HCV drugs.
IBS :: Lubiprostone may improve symptom relief rates in adults with IBS-C
A new study demonstrated that the active ingredient in AMITIZA? (lubiprostone), given 8 mcg twice a day, may improve symptom relief rates in adults with irritable bowel syndrome with constipation (IBS-C).
COPD :: Perforomist inhalation solution effective for COPD, emphysema, chronic bronchitis
Data presented at the International Conference of the American Thoracic Society (ATS) demonstrate that Perforomist? (formoterol fumarate) Inhalation Solution, delivered by nebulization, is an effective and well-tolerated new treatment option for patients suffering from emphysema or chronic bronchitis, otherwise known as Chronic Obstructive Pulmonary Disease (COPD).
Contraception :: Wyeth’s Lybrel a new oral contraceptive for women
Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), announced that two new scientific abstracts relating to the investigational, combination oral contraceptive Lybrel? (90 ?g levonorgestrel/20 ?g ethinyl estradiol tablets) were presented this week at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical Meeting in Washington, D.C.